TRA16 Inhibitors
Chemical inhibitors of TRA16 can be understood through the lens of their interactions with specific signaling pathways and cellular processes that are known to influence the function of the protein. Bisindolylmaleimide I and Go6983, as potent inhibitors of protein kinase C (PKC), inhibit TRA16 by potentially reducing PKC-dependent phosphorylation processes that TRA16 may rely on for its activity. Similarly, LY294002 and Wortmannin target the phosphoinositide 3-kinases (PI3K) pathway, which upon inhibition, could disrupt downstream signaling that is necessary for TRA16's functional activity. If TRA16's activity is contingent on PI3K signaling, the obstruction of this pathway by these inhibitors would lead to a direct decrease in TRA16's functional output.
On the other hand, U0126 and PD98059 specifically inhibit the mitogen-activated protein kinase kinase (MEK), which in turn may reduce extracellular signal-regulated kinase (ERK) signaling. If TRA16 is subject to regulation by the MEK/ERK pathway, then the inhibition of this pathway would lead to a reduction in ERK-mediated phosphorylation of TRA16, hence inhibiting its function. SB203580 and SP600125 bring about inhibition through targeting p38 MAPK and c-Jun N-terminal kinase (JNK) respectively. If TRA16 is part of the signaling cascade involving either p38 MAPK or JNK, the inhibition by these chemicals would obstruct the specific signaling route, leading to a decrease in TRA16 activity. Rapamycin, by inhibiting mTOR, could disrupt central cellular growth and metabolism pathways that may involve TRA16, thus inhibiting the protein. Y-27632, as a ROCK inhibitor, could similarly suppress TRA16 activity by impeding the Rho-associated protein kinase pathway. Lastly, ZM-447439's inhibition of Aurora kinases might interfere with cell cycle regulation mechanisms that could be essential for TRA16's function, thereby leading to its inhibition. Each chemical achieves inhibition of TRA16 by targeting these specific kinases and pathways that are integral to TRA16's role in the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is a potent and selective inhibitor of protein kinase C (PKC). Given that TRA16 is a protein that may rely on phosphorylation events for its function, the inhibition of PKC could result in decreased phosphorylation of TRA16, leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). If TRA16 function is dependent on signaling pathways involving PI3K, then LY294002 may inhibit TRA16 activity by disrupting these pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinase (ERK). Inhibition of MEK and subsequent ERK signaling could downregulate any ERK-mediated phosphorylation of TRA16, thereby inhibiting its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. If TRA16's activity is modulated through p38 MAPK signaling, then inhibition by SB203580 could lead to a functional decrease in TRA16 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). If TRA16 operates within JNK signaling pathways, its activity could be functionally inhibited by SP600125 through the disruption of these pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. Similar to LY294002, it can disrupt PI3K-dependent pathways, potentially leading to functional inhibition of TRA16 if it is involved in such pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. Since mTOR is a central player in cell growth and metabolism, inhibiting mTOR with rapamycin could lead to a functional inhibition of TRA16 if it is implicated in the mTOR pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of MEK. It acts similarly to U0126, and if TRA16 is regulated via MEK/ERK pathway, PD98059 could inhibit its function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of Rho-associated protein kinase (ROCK). If TRA16's function is modulated by the ROCK pathway, Y-27632 could inhibit TRA16 by disrupting this pathway. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor. If TRA16 is involved in cell cycle regulation where Aurora kinases play a role, this inhibitor could disrupt the pathway and inhibit TRA16 function. | ||||||